Arlo Radtke1, Finja Hennig1, Raphael Ikogho2, Johannes Hammel3, Petra Anheuser2,4, Christian Wülfing5, Gazanfer Belge1, Klaus-Peter Dieckmann2,5. 1. Faculty of Biology and Chemistry, University of Bremen, Bremen, Germany. 2. Department of Urology, Albertinen Krankenhaus, Hamburg, Germany. 3. Department of Urology, Klinikum Bremen-Mitte, Bremen, Germany. 4. Department of Urology, Asklepios Klinik St. Georg, Hamburg, Germany. 5. Department of Urology, Hodentumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg, Germany.
Abstract
BACKGROUND: Accumulating evidence suggests serum levels of microRNA (miR)-371a-3p to be a novel tumour marker of testicular germ cell tumours (GCTs). Presently, there is only limited information regarding the velocity of decline of serum levels in response to treatment. PATIENTS AND METHODS: Twenty-four patients with testicular GCT (20 seminoma, 4 nonseminoma, median age 40 years) with clinical stage 1 had measurements of serum levels of miR-371a-3p preoperatively and repeatedly on the following 3 days. Three had additional tests done within 24 h after surgery. Measurement results were analysed using descriptive statistical methods. RESULTS: Serum levels dropped to 2.62, 1.27, and 0.47% of the preoperative level within 1, 2, and 3 days, respectively. The computed half-life amounts to 3.7-7 h. The velocity of decay is significantly associated with tumour size. CONCLUSIONS: Serum-levels of miR-371a-3p have a short half-life of less than 12 h. The rapid decay after treatment represents a valuable feature confirming the usefulness of miR-371a-3p as a valuable serum biomarker of GCT.
BACKGROUND: Accumulating evidence suggests serum levels of microRNA (miR)-371a-3p to be a novel tumour marker of testicular germ cell tumours (GCTs). Presently, there is only limited information regarding the velocity of decline of serum levels in response to treatment. PATIENTS AND METHODS: Twenty-four patients with testicular GCT (20 seminoma, 4 nonseminoma, median age 40 years) with clinical stage 1 had measurements of serum levels of miR-371a-3p preoperatively and repeatedly on the following 3 days. Three had additional tests done within 24 h after surgery. Measurement results were analysed using descriptive statistical methods. RESULTS: Serum levels dropped to 2.62, 1.27, and 0.47% of the preoperative level within 1, 2, and 3 days, respectively. The computed half-life amounts to 3.7-7 h. The velocity of decay is significantly associated with tumour size. CONCLUSIONS: Serum-levels of miR-371a-3p have a short half-life of less than 12 h. The rapid decay after treatment represents a valuable feature confirming the usefulness of miR-371a-3p as a valuable serum biomarker of GCT.
Authors: Klaus-Peter Dieckmann; Arlo Radtke; Meike Spiekermann; Thomas Balks; Cord Matthies; Pascal Becker; Christian Ruf; Christoph Oing; Karin Oechsle; Carsten Bokemeyer; Johannes Hammel; Sebastian Melchior; Werner Wosniok; Gazanfer Belge Journal: Eur Urol Date: 2016-08-02 Impact factor: 20.096
Authors: C Massard; A Kramar; J Beyer; J T Hartmann; A Lorch; J L Pico; G Rosti; J P Droz; K Fizazi Journal: Ann Oncol Date: 2012-10-26 Impact factor: 32.976
Authors: A Radtke; J-F Cremers; S Kliesch; S Riek; K Junker; S A Mohamed; P Anheuser; G Belge; K-P Dieckmann Journal: J Cancer Res Clin Oncol Date: 2017-08-17 Impact factor: 4.553
Authors: Matthew J Murray; Emma Bell; Katie L Raby; Martin A Rijlaarsdam; Ad J M Gillis; Leendert H J Looijenga; Helen Brown; Benoit Destenaves; James C Nicholson; Nicholas Coleman Journal: Br J Cancer Date: 2015-12-15 Impact factor: 7.640
Authors: John T Lafin; Matthew J Murray; Nicholas Coleman; A Lindsay Frazier; James F Amatruda; Aditya Bagrodia Journal: Mol Diagn Ther Date: 2021-04-24 Impact factor: 4.074
Authors: Nirmish Singla; John T Lafin; Rashed A Ghandour; Samuel Kaffenberger; James F Amatruda; Aditya Bagrodia Journal: Curr Opin Urol Date: 2019-07 Impact factor: 2.309
Authors: Fei Ye; Darren R Feldman; Alisa Valentino; Rachel So; Maria Bromberg; Shah Khan; Samuel A Funt; Joel Sheinfeld; David B Solit; Melissa S Pessin; Ellinor I Peerschke Journal: J Mol Diagn Date: 2022-08 Impact factor: 5.341
Authors: Liang Cheng; Peter Albers; Daniel M Berney; Darren R Feldman; Gedske Daugaard; Timothy Gilligan; Leendert H J Looijenga Journal: Nat Rev Dis Primers Date: 2018-10-05 Impact factor: 52.329
Authors: Lucia Nappi; Marisa Thi; Amy Lum; David Huntsman; Bernie J Eigl; Christopher Martin; Brock O'Neil; Benjamin L Maughan; Kim Chi; Alan So; Peter C Black; Martin Gleave; Alex W Wyatt; Jean Michel Lavoie; Daniel Khalaf; Robert Bell; Siamak Daneshmand; Robert J Hamilton; Ricardo R N Leao; Craig Nichols; Christian Kollmannsberger Journal: J Clin Oncol Date: 2019-09-25 Impact factor: 50.717
Authors: Klaus-Peter Dieckmann; Arlo Radtke; Lajos Geczi; Cord Matthies; Petra Anheuser; Ulrike Eckardt; Jörg Sommer; Friedemann Zengerling; Emanuela Trenti; Renate Pichler; Hanjo Belz; Stefan Zastrow; Alexander Winter; Sebastian Melchior; Johannes Hammel; Jennifer Kranz; Marius Bolten; Susanne Krege; Björn Haben; Wolfgang Loidl; Christian Guido Ruf; Julia Heinzelbecker; Axel Heidenreich; Jann Frederik Cremers; Christoph Oing; Thomas Hermanns; Christian Daniel Fankhauser; Silke Gillessen; Hermann Reichegger; Richard Cathomas; Martin Pichler; Marcus Hentrich; Klaus Eredics; Anja Lorch; Christian Wülfing; Sven Peine; Werner Wosniok; Carsten Bokemeyer; Gazanfer Belge Journal: J Clin Oncol Date: 2019-03-15 Impact factor: 44.544
Authors: W P A Boellaard; A J M Gillis; G J L H van Leenders; H Stoop; T van Agthoven; L C J Dorssers; M Dinkelman-Smit; J L Boormans; L H J Looijenga Journal: Andrology Date: 2019-02-20 Impact factor: 3.842